Selected research
Market Analysis & Forecast
Global Extended-release Medication Market Analysis and Forecast 2026-2032
Market perspective
The global Extended-release Medication market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Extended-release Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Extended-release Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Extended-release Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Extended-release Medication is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Extended-release Medication include Shanghai Shyndec Pharmaceutical, Takeda, Sanofi, Zhuhai Rundu Pharmaceutical, Johnson & Johnson, Novartis, Pfizer, Bayer and AbbVie, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Extended-release Medication, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Extended-release Medication, also provides the revenue of main regions and countries. Of the upcoming market potential for Extended-release Medication, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Extended-release Medication revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Extended-release Medication market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Extended-release Medication revenue, projected growth trends, production technology, application and end-user industry.
Extended-release Medication Segment by Company
Shanghai Shyndec Pharmaceutical
Takeda
Sanofi
Zhuhai Rundu Pharmaceutical
Johnson & Johnson
Novartis
Pfizer
Bayer
AbbVie
AstraZeneca
Endo Pharmaceuticals
Collegium Pharmaceutical, Inc
China Res Double-Crane
Extended-release Medication Segment by Type
Original Medication
Generic Medication
Extended-release Medication Segment by Application
Hospital
Drugstore
Other
Extended-release Medication Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Extended-release Medication market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Extended-release Medication and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Extended-release Medication.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Extended-release Medication in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Extended-release Medication company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Extended-release Medication revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Original Medication
- Generic Medication
Applications
- Hospital
- Drugstore
- Other
Companies covered
- Shanghai Shyndec Pharmaceutical
- Takeda
- Sanofi
- Zhuhai Rundu Pharmaceutical
- Johnson & Johnson
- Novartis
- Pfizer
- Bayer
- AbbVie
- AstraZeneca
- Endo Pharmaceuticals
- Collegium Pharmaceutical, Inc
- China Res Double-Crane
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Extended-release Medication Market by Type
- 1.2.1 Global Extended-release Medication Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Original Medication
- 1.2.3 Generic Medication
- 1.3 Extended-release Medication Market by Application
- 1.3.1 Global Extended-release Medication Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Drugstore
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Extended-release Medication Market Dynamics
- 2.1 Extended-release Medication Industry Trends
- 2.2 Extended-release Medication Industry Drivers
- 2.3 Extended-release Medication Industry Opportunities and Challenges
- 2.4 Extended-release Medication Industry Restraints
3 Global Growth Perspective
- 3.1 Global Extended-release Medication Market Perspective (2021-2032)
- 3.2 Global Extended-release Medication Growth Trends by Region
- 3.2.1 Global Extended-release Medication Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Extended-release Medication Market Size by Region (2021-2026)
- 3.2.3 Global Extended-release Medication Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Extended-release Medication Revenue by Players
- 4.1.1 Global Extended-release Medication Revenue by Players (2021-2026)
- 4.1.2 Global Extended-release Medication Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Extended-release Medication Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Extended-release Medication Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Extended-release Medication Key Players Headquarters & Area Served
- 4.4 Global Extended-release Medication Players, Product Type & Application
- 4.5 Global Extended-release Medication Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Extended-release Medication Market CR5 and HHI
- 4.6.3 2025 Extended-release Medication Tier 1, Tier 2, and Tier 3
5 Extended-release Medication Market Size by Type
- 5.1 Global Extended-release Medication Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Extended-release Medication Revenue by Type (2021-2032)
- 5.3 Global Extended-release Medication Revenue Market Share by Type (2021-2032)
6 Extended-release Medication Market Size by Application
- 6.1 Global Extended-release Medication Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Extended-release Medication Revenue by Application (2021-2032)
- 6.3 Global Extended-release Medication Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Shanghai Shyndec Pharmaceutical
- 7.1.1 Shanghai Shyndec Pharmaceutical Company Information
- 7.1.2 Shanghai Shyndec Pharmaceutical Business Overview
- 7.1.3 Shanghai Shyndec Pharmaceutical Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.1.4 Shanghai Shyndec Pharmaceutical Extended-release Medication Product Portfolio
- 7.1.5 Shanghai Shyndec Pharmaceutical Recent Developments
- 7.2 Takeda
- 7.2.1 Takeda Company Information
- 7.2.2 Takeda Business Overview
- 7.2.3 Takeda Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.2.4 Takeda Extended-release Medication Product Portfolio
- 7.2.5 Takeda Recent Developments
- 7.3 Sanofi
- 7.3.1 Sanofi Company Information
- 7.3.2 Sanofi Business Overview
- 7.3.3 Sanofi Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.3.4 Sanofi Extended-release Medication Product Portfolio
- 7.3.5 Sanofi Recent Developments
- 7.4 Zhuhai Rundu Pharmaceutical
- 7.4.1 Zhuhai Rundu Pharmaceutical Company Information
- 7.4.2 Zhuhai Rundu Pharmaceutical Business Overview
- 7.4.3 Zhuhai Rundu Pharmaceutical Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.4.4 Zhuhai Rundu Pharmaceutical Extended-release Medication Product Portfolio
- 7.4.5 Zhuhai Rundu Pharmaceutical Recent Developments
- 7.5 Johnson & Johnson
- 7.5.1 Johnson & Johnson Company Information
- 7.5.2 Johnson & Johnson Business Overview
- 7.5.3 Johnson & Johnson Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.5.4 Johnson & Johnson Extended-release Medication Product Portfolio
- 7.5.5 Johnson & Johnson Recent Developments
- 7.6 Novartis
- 7.6.1 Novartis Company Information
- 7.6.2 Novartis Business Overview
- 7.6.3 Novartis Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.6.4 Novartis Extended-release Medication Product Portfolio
- 7.6.5 Novartis Recent Developments
- 7.7 Pfizer
- 7.7.1 Pfizer Company Information
- 7.7.2 Pfizer Business Overview
- 7.7.3 Pfizer Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.7.4 Pfizer Extended-release Medication Product Portfolio
- 7.7.5 Pfizer Recent Developments
- 7.8 Bayer
- 7.8.1 Bayer Company Information
- 7.8.2 Bayer Business Overview
- 7.8.3 Bayer Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.8.4 Bayer Extended-release Medication Product Portfolio
- 7.8.5 Bayer Recent Developments
- 7.9 AbbVie
- 7.9.1 AbbVie Company Information
- 7.9.2 AbbVie Business Overview
- 7.9.3 AbbVie Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.9.4 AbbVie Extended-release Medication Product Portfolio
- 7.9.5 AbbVie Recent Developments
- 7.10 AstraZeneca
- 7.10.1 AstraZeneca Company Information
- 7.10.2 AstraZeneca Business Overview
- 7.10.3 AstraZeneca Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.10.4 AstraZeneca Extended-release Medication Product Portfolio
- 7.10.5 AstraZeneca Recent Developments
- 7.11 Endo Pharmaceuticals
- 7.11.1 Endo Pharmaceuticals Company Information
- 7.11.2 Endo Pharmaceuticals Business Overview
- 7.11.3 Endo Pharmaceuticals Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.11.4 Endo Pharmaceuticals Extended-release Medication Product Portfolio
- 7.11.5 Endo Pharmaceuticals Recent Developments
- 7.12 Collegium Pharmaceutical, Inc
- 7.12.1 Collegium Pharmaceutical, Inc Company Information
- 7.12.2 Collegium Pharmaceutical, Inc Business Overview
- 7.12.3 Collegium Pharmaceutical, Inc Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.12.4 Collegium Pharmaceutical, Inc Extended-release Medication Product Portfolio
- 7.12.5 Collegium Pharmaceutical, Inc Recent Developments
- 7.13 China Res Double-Crane
- 7.13.1 China Res Double-Crane Company Information
- 7.13.2 China Res Double-Crane Business Overview
- 7.13.3 China Res Double-Crane Extended-release Medication Revenue and Gross Margin (2021-2026)
- 7.13.4 China Res Double-Crane Extended-release Medication Product Portfolio
- 7.13.5 China Res Double-Crane Recent Developments
8 North America
- 8.1 North America Extended-release Medication Revenue (2021-2032)
- 8.2 North America Extended-release Medication Revenue by Type (2021-2032)
- 8.2.1 North America Extended-release Medication Revenue by Type (2021-2026)
- 8.2.2 North America Extended-release Medication Revenue by Type (2027-2032)
- 8.3 North America Extended-release Medication Revenue Share by Type (2021-2032)
- 8.4 North America Extended-release Medication Revenue by Application (2021-2032)
- 8.4.1 North America Extended-release Medication Revenue by Application (2021-2026)
- 8.4.2 North America Extended-release Medication Revenue by Application (2027-2032)
- 8.5 North America Extended-release Medication Revenue Share by Application (2021-2032)
- 8.6 North America Extended-release Medication Revenue by Country
- 8.6.1 North America Extended-release Medication Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Extended-release Medication Revenue by Country (2021-2026)
- 8.6.3 North America Extended-release Medication Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Extended-release Medication Revenue (2021-2032)
- 9.2 Europe Extended-release Medication Revenue by Type (2021-2032)
- 9.2.1 Europe Extended-release Medication Revenue by Type (2021-2026)
- 9.2.2 Europe Extended-release Medication Revenue by Type (2027-2032)
- 9.3 Europe Extended-release Medication Revenue Share by Type (2021-2032)
- 9.4 Europe Extended-release Medication Revenue by Application (2021-2032)
- 9.4.1 Europe Extended-release Medication Revenue by Application (2021-2026)
- 9.4.2 Europe Extended-release Medication Revenue by Application (2027-2032)
- 9.5 Europe Extended-release Medication Revenue Share by Application (2021-2032)
- 9.6 Europe Extended-release Medication Revenue by Country
- 9.6.1 Europe Extended-release Medication Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Extended-release Medication Revenue by Country (2021-2026)
- 9.6.3 Europe Extended-release Medication Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Extended-release Medication Revenue (2021-2032)
- 10.2 China Extended-release Medication Revenue by Type (2021-2032)
- 10.2.1 China Extended-release Medication Revenue by Type (2021-2026)
- 10.2.2 China Extended-release Medication Revenue by Type (2027-2032)
- 10.3 China Extended-release Medication Revenue Share by Type (2021-2032)
- 10.4 China Extended-release Medication Revenue by Application (2021-2032)
- 10.4.1 China Extended-release Medication Revenue by Application (2021-2026)
- 10.4.2 China Extended-release Medication Revenue by Application (2027-2032)
- 10.5 China Extended-release Medication Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Extended-release Medication Revenue (2021-2032)
- 11.2 Asia Extended-release Medication Revenue by Type (2021-2032)
- 11.2.1 Asia Extended-release Medication Revenue by Type (2021-2026)
- 11.2.2 Asia Extended-release Medication Revenue by Type (2027-2032)
- 11.3 Asia Extended-release Medication Revenue Share by Type (2021-2032)
- 11.4 Asia Extended-release Medication Revenue by Application (2021-2032)
- 11.4.1 Asia Extended-release Medication Revenue by Application (2021-2026)
- 11.4.2 Asia Extended-release Medication Revenue by Application (2027-2032)
- 11.5 Asia Extended-release Medication Revenue Share by Application (2021-2032)
- 11.6 Asia Extended-release Medication Revenue by Country
- 11.6.1 Asia Extended-release Medication Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Extended-release Medication Revenue by Country (2021-2026)
- 11.6.3 Asia Extended-release Medication Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Extended-release Medication Revenue (2021-2032)
- 12.2 SAMEA Extended-release Medication Revenue by Type (2021-2032)
- 12.2.1 SAMEA Extended-release Medication Revenue by Type (2021-2026)
- 12.2.2 SAMEA Extended-release Medication Revenue by Type (2027-2032)
- 12.3 SAMEA Extended-release Medication Revenue Share by Type (2021-2032)
- 12.4 SAMEA Extended-release Medication Revenue by Application (2021-2032)
- 12.4.1 SAMEA Extended-release Medication Revenue by Application (2021-2026)
- 12.4.2 SAMEA Extended-release Medication Revenue by Application (2027-2032)
- 12.5 SAMEA Extended-release Medication Revenue Share by Application (2021-2032)
- 12.6 SAMEA Extended-release Medication Revenue by Country
- 12.6.1 SAMEA Extended-release Medication Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Extended-release Medication Revenue by Country (2021-2026)
- 12.6.3 SAMEA Extended-release Medication Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst